Wednesday, July 8, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

BPX-601

Phase 1 · mab · Metastatic Castration-resistant Prostate Cancer

BPX-601 for Metastatic Castration-resistant Prostate Cancer is a Phase 1 program (mab) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Internal code BP-012

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 1
Modality
mab
Indication
Metastatic Castration-resistant Prostate Cancer
Status
terminated
Trials
1

Clinical trials